Profile Response Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

Molecular Profile Unknown unknown
Therapy Cisplatin + Gemcitabine + Necitumumab
Indication/Tumor Type lung squamous cell carcinoma
Response Type not applicable


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown lung squamous cell carcinoma not applicable Cisplatin + Gemcitabine + Necitumumab FDA approved Actionable In a Phase III clinical trial that supported FDA approval, treatment with Portrazza (necitumumab), in combination with gemcitabine and cisplatin, resulted in an increased median overall survival of 11.5 months in squamous NSCLC patients, compared to 9.9 months with gemcitabine and cisplatin alone (PMID: 26045340). detail... 26045340
PubMed Id Reference Title Details
(26045340) Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Full reference...
Portrazza (necitumumab) FDA Drug Label Full reference...